Intensification of chemotherapy using block therapies as consolidation and reinduction therapies for acute lymphoblastic leukemia during childhood

International Journal of Hematology

Volumn 74, Issue 2, 2001, Pages 165-172

  Hara, Junichi ^a,o   Park, Yong Dong ^b   Yoshioka, Akira ^b   Yumura Yagi, Keiko ^c   Koudera, Urara ^d   Hosoi, Gaku ^c   Sako, Masahiro ^e   Kosaka, Yoshiyuki ^f   Sano, Kimihiko ^f   Misu, Hideo ^g   Mabuchi, Osamu ^g   Aoyagi, Noriyuki ^h   Yamamoto, Masuji ⁱ   Tawa, Akio ^j   Miyata, Hiroshi ^k   Tanaka, Haruki ^l   Kikkawa, Makiko ^m   Shimodera, Mutsuro ⁿ   Kawa Ha, Keisei ^d  

^a OSAKA UNIVERSITY   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

^c RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^d KANSAI MEDICAL UNIVERSITY   (Japan)

^e OSAKA CITY GENERAL HOSPITAL   (Japan)

^f KOBE UNIVERSITY   (Japan)

^g KOBE CHILDREN S HOSPITAL   (Japan)

^h WAKAYAMA MEDICAL UNIVERSITY   (Japan)

ⁱ HYOGO COLLEGE OF MEDICINE   (Japan)

^j OSAKA NATIONAL HOSPITAL   (Japan)

^k KINKI UNIVERSITY   (Japan)

^l OSAKA RED CROSS HOSPITAL   (Japan)

^m School of Medicine   (Japan)

ⁿ TAKATSUKI RED CROSS HOSPITAL   (Japan)

^o OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Acute lymphoblastic leukemia; Block therapy; Chemotherapy; Childhood; Clinical study

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; B CELL LEUKEMIA; CHILD; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; INFANT; MALE; MORTALITY; PRESCHOOL CHILD; RISK FACTOR; SURVIVAL RATE; T CELL LEUKEMIA; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; LEUKEMIA, B-CELL; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LEUKEMIA, T-CELL; MALE; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0035430702     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02982000     Document Type: Article

References (26)

1. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000; 95:3310-3322.
2. Kamps WA, Bokkerink JP, Hahlen K, et al. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991). Blood. 1999; 94:1226-1236.
3. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998;339:605-615.
4. Mahoney DH Jr, Shuster J, Nitschke R, et al. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial. J Clin Oncol. 1998;16:246-254.
5. Chessells JM, Bailey C, Richards SM. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia. Lancet. 1995; 345:143-148.
6. Evans WE, Relling MV, Rodman JH, et al. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med. 1998;338:499-505.
7. Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338:1663-1671.
8. Horibe K, Hara J, Yagi K, et al. Prognostic factors in childhood acute lymphoblastic leukemia in Japan. Japan Association of Childhood Leukemia Study. Int J Hematol. 2000;72:61-68.
9. Horibe K, Komada Y. Treatment outcome of standard risk acute lymphoblastic leukemia during childhood. Jpn J Pediatr Hematol. 1996;10:359-366.
10. Matsuzaki A, Ishii E, Okamura J, et al.Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan. Med Pediatr Oncol 1996;26:10-19.
11. Pui CH, Boyett JM, Rivera GK, et al. Long-term results of total therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia. 2000; 14:2286-2294.
12. Reiter A, Schrappe M, Ludwig WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood. 1994;84:3122-3133.
13. Rivera GK, Raimondi SC, Hancock ML, et al. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet. 1991; 337:61-66.
14. Niemeyer CM, Gelber RD, Tarbell NJ, et al. Low-dose versus high-dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (Protocol 81-01 update). Blood. 1991;78: 2514-2519.
15. Gaynon PS, Steinherz PG, Bleyer WA, et al. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106. J Clin Oncol. 1993;11:2234-2242.
16. Muggia FM, Green MD. New anthracycline antitumor antibiotics. Cm Rev Oncol Hematol. 1991;11:43-64.
17. Umezawa K, Kunimoto S, Takeuchi T. Experimental studies of new anthracyclines: aclacinomycin, THP-adriamycin and ditrisarubicins. Biomed Pharmacother. 1987;41:206-213.
18. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. 4′-O-tetrahydropyrany-ladriamycin as a potential new antitumor agent. Cancer Res. 1982; 42:1462-1467.
19. Dabich L, Bull FE, Beltran G, et al. Phase II evaluation of aclarubicin in refractory adult acute leukemia: a Southwest Oncology Group Study. Cancer Treat Rep. 1986;70:967-969.
20. Dhingra K, Frye D, Newman RA, et al. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. Clin Cancer Res. 1995;1:691-697.
21. Dittrich C, Baur M, Mader R, et al. Phase I-II study on weekly administration of pirarubicin in patients with metastatic breast cancer. Am J Clin Oncol. 1990;13(suppl 1):S29-S29.
22. Hara J, Hosoi G, Okamura T, et al. CD33+ B-cell precursor acute lymphoblastic leukemia in children: a distinct subgroup of B-cell precursor acute lymphoblastic leukemia. Int J Hematol. 1995;61: 77-84
23. Hara J, Matsuda Y, Fujisaki H, et al. Expression of adhesion molecules in childhood B-lineage-cell neoplasms. Int J Hematol. 2000; 72:69-73.
24. Gajjar A, Ribeiro R, Hancock ML, et al. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood. 1995; 86:1292-1295.
25. Toyoda Y, Manabe A, Tsuchida M, et al. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol. 2000;18: 1508-1516.
26. Nibu K, Yanai F, Okamura J, et al. An effective salvage regimen with aclarubicin for daunorubicin-resistant acute non-lymphocytic leukemia in children. Pediatr Hematol Oncol. 1995;12: 251-258.